Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Stock Information for Cadrenal Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.